REFERENCES

1. Farolch-Prats L, Nome-Chamorro C. Facial contouring by using dermal fillers and botulinum toxin A: a practical approach. Aesthetic Plast Surg 2019;43:793-802.

2. Jones D, Tezel A, Borrell M. In vitro resistance to degradation of hyaluronic acid dermal fillers by ovine testicular hyaluronidase. Dermatol Surg 2010;36:804-9.

3. Urdiales-Galvez F, Delgado NE, Figueiredo V, Lajo-Plaza JV, Mira M, et al. Treatment of soft tissue filler complications: expert consensus recommendations. Aesthetic Plast Surg 2018;42:498-510.

4. Cavallini M, Gazzola R, Metalla M, Vaienti L. The role of hyaluronidase in the treatment of complications from hyaluronic acid dermal fillers. Aesthet Surg J 2013;33:1167-74.

5. Hylenex [Package insert]. San Diego, CA: Halozyme Therapeutics, Inc; 2012.

6. Rao V, Chi S, Woodward J. Reversing facial fillers: interactions between hyaluronidase and commercially available hyaluronic-acid based fillers. J Drugs Dermatol 2014;13:1053-6.

7. Lambros V. The use of hyaluronidase to reverse the effects of hyaluronic acid filler. Plast Reconstr Surg 2004;114:227.

8. Surek CC, Said SA, Perry JD, Zins JE. Retrobulbar injection for hyaluronic acid gel filler-induced blindness: a review of efficacy and technique. Aesthetic Plast Surg 2019;43:1034-40.

9. Hirsch RJ, Cohen JL, Carruthers JDA. Successful management of an unusual presentation of impending necrosis following a hyaluronic acid injection embolus and a proposed algorithm for management of hyaluronidase. Dermatol Surg 2007;33:357-60.

10. Paap MK, Milman T, Ugradar S, Goldberg R, Silkiss RZ. Examining the role of retrobulbar hyaluronidase in reversing filler induced blindness: a systemic review. Ophthalmic Plast Reconstr Surg ;36:231-8.

11. Paap MK, Milman T, Ugradar S, Silkiss RZ. Assessing retrobulbar hyaluronidase as a treatment for filler-induced blindness in a cadaver model. Plast Reconstr Surg 2019;144:315-20.

12. Sall I, Ferard G. Comparison of the sensitivity of 11 crosslinked hyaluronic acid gels to bovine testis hyaluronidase. Polymer Degradation and Stability 2007;92:915-9.

13. Gold MH. Use of hyaluronic acid fillers for the treatment of the aging face. Clinical Interventions in Aging 2007;2:369-76.

14. Cavallini M, Papagni M, Trocchi G. Sensitivity of hyaluronic acid fillers to hyaluronidase: an in vitro analysis. J Clin Exp Dermatol Res 2020;11:517.

15. Flynn TC, Thompson DH, Hyun SH. Molecular weight, analyses and enzymatic degradation profiles of the soft-tissue fillers Belotero Balance, Restylane, and Juvederm Ultra. Plast Reconstr Surg 2013;132:22S-32.

16. Shumate GT, Chopra R, Jones D, Messina DJ, Hee CK. In vivo degradation of crosslinked hyaluronic acid fillers by exogenous hyaluronidases. Dermatol Surg 2018;44:1075-83.

17. Buhren BA, Schrumpf H, Bolke E, Kammers K, Gerber PA. Standardized in vitro analysis of the degradability of hyaluronic acid fillers by hyaluronidase. Eur J Med Res 2018;23:37.

18. Juhasz MLW, Levin MK, Marmur ES. The kinetics of reversible hyaluronic acid filler injection treated with hyaluronidase. Dermatol Surg 2017;43:841-7.

19. Dunn AL, Heavner JE, Racz G, Day M. Hyaluronidase: a review of approved formulations, indications and off-label use in chronic pain management. Expert Opin Biol Ther 2010;10:127-31.

20. Weber GC, Buhren BA, Schrumpf H, Wohlrab J, Gerber PA. Clinical applications of hyaluronidase. In: Labrou N, editor. Therapeutic enzymes: function and clinical implications. New York: Springer; 2019. pp. 255-78.

21. Food and Drug Administration. Dermal Fillers Approved by the Center for Devices and Radiological Health. Available from: https://www.fda.gov/medical-devices/cosmetic-devices/dermal-fillers-approved-center-devices-and-radiological-health [Last accessed on 6 Jul 2020].

22. Gold MH. What’s new in fillers in 2010? J Clin Aesthet Dermatol 2010;3:36-45.

23. Agerup B, Berg P, Akermark C. Non-animal stabilized hyaluronic acid: a new formulation for the treatment of osteoarthritis. BioDrugs 2005;19:23-30.

24. Mansouri Y, Goldenberg G. Update on hyaluronic acid fillers for facial rejuvenation. Cutis 2015;96:85-8.

25. Philipp-Dormston WG, Wong C, Schuster B, Larsson MK, Podda M. Evaluating perceived naturalness of facial expression after fillers to the nasolabial folds and lower face with standardized video and photography. Dermatol Surg 2018;44:826-32.

26. U.S. National Library of Medicine. Study to Evaluate Satisfaction After Treatment with Kysse. Available from: https://clinicaltrials.gov/ct2/show/NCT03967444 [Last accessed on 24 Apr 2020].

27. Allemann IB, Baumann L. Hyaluronic acid gel (Juvéderm) preparations in the treatment of facial wrinkles and folds. Clin Interv Aging 2008;3:629-34.

28. Monheit G, Beer K, Hardas B, Grimes PE, Weichman BM, et al. Safety and effectiveness of the hyaluronic acid dermal filler VYC-17.5L for nasolabial folds: results of a randomized, controlled study. Dermatol Surg 2018;44:670-8.

29. Devgan L. Abstract: Juvéderm Volbella for use in periorbital volumization. Plast Reconstr Surg Glob Open 2017;5:192-3.

30. Niforos F, Ogilvie P, Cavallini M, Leys C, Chantrey J, et al. VYC-12 injectable gel is safe and effective for improvement of facial skin topography: a prospective study. Clin Cosmet Investig Dermatol 2019;12:791-8.

31. Prasetyo AD, Prager W, Rubin MG, Moretti EA, Nikolis A. Hyaluronic acid fillers with cohesive polydensfied matrix for soft-tissue augmentation and rejuvenation: a literature review. Clin Cosmet Investig Dermatol 2016;9:257-80.

32. Palm MD. Filler frontier: what’s new and heading West to the US market. Semin Cutan Med Surg 2014;33:157-63.

33. Lee A, Grummer SE, Kriegel D, Marmur E. Hyaluronidase. Dermatol Surg 2010;36:1071-7.

34. Landau M. Hyaluronidase caveats in treating filler complications. Dermatol Surg 2015;41:S347-53.

35. Delorenzi C. Complications of injectible fillers, part I. Aesthet Surg J 2013;33:561-75.

36. Vartanian AJ, Frankel AS, Rubin MG. Injected hyaluronidase reduces Restylane-mediated cutaneous augmentation. Arch Facial Plast Surg 2005;7:231-7.